What happened with COGT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cogent Biosciences is a clinical-stage biotechnology company whose business centers on bezuclastinib. This experimental drug is designed to block mutated KIT and is being developed for non-advanced and advanced systemic mastocytosis and gastrointestinal stromal tumors. The company’s path to product revenue depends heavily on getting bezuclastinib approved and bringing it to market.
At the end of 2025, Cogent had no drugs approved for sale and had earned no product-sales revenue. It had submitted its first U.S. marketing application, for non-advanced systemic mastocytosis; a commercial launch remained conditional on regulatory approval. Its limited historical revenue came from funding arrangements with a former collaboration partner, while share offerings and debt have been its main sources of operating funding.
If bezuclastinib reaches the market, sales will depend on doctors and patients adopting it and on government and private insurers covering treatment at adequate reimbursement levels. Cogent owns no manufacturing facilities and relies on outside manufacturers. Bezuclastinib’s active ingredient and finished drug currently come from sole-source suppliers, making those suppliers important to both development and future commercial supply.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cogent’s prospects hinge chiefly on bezuclastinib approval and adoption in systemic mastocytosis and GIST, where Ono Pharmaceuticals’ Deciphera subsidiary also competes with ripretinib.
Sanofi already sells a treatment for the patients Cogent hopes to reach: its Blueprint Medicines markets avapritinib for both nonadvanced and advanced systemic mastocytosis. Adoption of that medicine is a competitive benchmark for Cogent’s still-unapproved bezuclastinib.
Novartis sells medicines in both of Cogent’s main disease markets: midostaurin for advanced systemic mastocytosis with the KIT D816V mutation, and imatinib for GIST. Imatinib is the first-line standard for unresectable or metastatic GIST, placing Novartis earlier in the treatment path than Cogent’s proposed second-line bezuclastinib combination.
GSK’s GIST trial results matter to Cogent because both companies are developing drugs that block tyrosine kinases to treat these tumors. Progress in GSK’s candidate could change the competition facing bezuclastinib, rather than reflect demand for GSK’s existing medicines and vaccines.
Pfizer supplies the GIST medicine Cogent seeks to improve upon: its sunitinib is the second-line standard after progression on imatinib. Cogent is developing bezuclastinib alongside sunitinib, so the key comparison is the combination versus the existing treatment, not replacing Pfizer’s drug outright.
Tyra Biosciences competes with Cogent’s clinical FGFR2/3 program, rather than its lead bezuclastinib business. Tyra’s TYRA-200, an oral drug candidate for FGFR2-driven intrahepatic cholangiocarcinoma, is the program to watch for competition in this part of Cogent’s pipeline.
Incyte already sells pemigatinib for FGFR-related cholangiocarcinoma, competing with Cogent’s clinical FGFR program, and also pursues JAK2 therapies that overlap Cogent’s preclinical work. Its pemigatinib business and JAK2 development news speak to competition beyond Cogent’s lead bezuclastinib program.
Prelude Therapeutics competes with Cogent’s preclinical JAK2 work through its JAK2 V617F inhibitor program, not Cogent’s lead bezuclastinib program. Incyte has an option to buy that program, while Prelude retains ownership and continues development during the option period; watch both its development progress and whether Incyte completes the purchase.
Fed Interest Rate Decision
Cogent’s policy-rate backdrop affects the interest income it earns on cash equivalents and marketable securities, while also influencing the cost of future borrowing.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates may support more interest income on Cogent’s cash and securities, but could make future borrowing more costly if it needs additional funding.
If it comes in below expectations
Lower rates may reduce interest income on Cogent’s cash and securities, but could make future borrowing less costly if it needs additional funding.
Sanofi earningsSNY
Sanofi’s report shows how its marketed avapritinib is selling for systemic mastocytosis, a direct commercial benchmark for Cogent Biosciences’ unapproved bezuclastinib.
Look for Sanofi’s reported avapritinib sales or use, and whether demand comes from both nonadvanced and advanced systemic mastocytosis. Strong demand across both settings would show that an available treatment is drawing patients and set a high adoption bar for Cogent; weaker demand would point to less commercial pull from the existing drug, but would not establish how bezuclastinib would fare if approved.
Pfizer Inc. earningsPFE
Pfizer’s report shows how sunitinib is selling; it is an established second-line GIST treatment and part of Cogent Biosciences’ bezuclastinib combination, not a drug the combination simply replaces.
Look for Pfizer’s reported sunitinib sales or use, separate from its overall business. Continued demand would show that second-line GIST has an established treatment choice; if approved, Cogent’s combination would need to show that adding bezuclastinib brings enough value, not that it replaces sunitinib. Weaker demand would indicate less pull for the existing drug, but Pfizer’s report cannot establish whether the combination works or will be approved.
Cogent Biosciences, Inc. earningsThis company
Cogent Biosciences has no approved products or product-sales revenue, so this report shows what it is spending to advance bezuclastinib toward approval and launch, and how quickly that uses cash.
Read research and development and general and administrative costs alongside cash used in operations. Lower costs or a smaller operating cash outflow would show that spending on trials, regulatory work and launch preparation is easing; increases would mean those steps are consuming more resources. Then compare the cash and marketable securities balance with the company’s stated runway into 2028: this shows how launch preparation weighs on funding, not whether the drug will be approved or launch on schedule.
